BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
BioMarin Pharma (BMRN) Tops Q4 EPS by 17c, Offers FY Guidance
February 26, 2020 4:08 PM ESTBioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.08, $0.17 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $454.4 million versus the consensus estimate of $459.33 million.
GUIDANCE:
BioMarin Pharma sees FY2020 revenue of $1.95-2.05 billion, versus the consensus of $1.95... More
